Abstract
Background Growing evidence has proposed prognostic value of immune infiltration in gastrointestinal stromal tumors (GISTs). Therefore, we aimed to develop a novel immune-based prognostic classifier (IPC) to help better stratify and predict prognosis of GISTs.
Methods The gene expression profiles of 22 immune features of GISTs were detected from GEO dataset. The IPC was constructed using the LASSO Cox regression model and validated in a cohort including 54 patients with complete resection of localized primary GISTs via immunohistochemistry process. The performance assessment of the IPC was estimated, then compared with conventional risk prognostic criteria.
Results The IPC was established based on 4 features: CD8, CD8/CD3, CD68, CD163/CD68 and validated to be an independent predictor of RFS for GISTs (HR 5.2, 95%CI 1.99-13.65). Significant differences were found between low- and high-IPC group in 5-year RFS (92.6% vs 48.1%, p < 0.001). Using the IPC, the high-risk group of the Modified NIH classification was split into two groups in 5-year RFS (low-IPC vs high-IPC, 85.7% vs 30.0%, p < 0.001). The IPC showed a higher net benefit than both “treat all” or “treat none” methods for the threshold probability within a range of 0-0.62 and exhibited a performance (AUC 0.842) superior to modified NIH classification (AUC 0.763).
Conclusion The IPC was effective to predict RFS after complete resection of localized primary GISTs, adding prognostic value to the routine clinical prognostic criteria. Prospective studies are needed to further validate the analytical accuracy and practicability of the IPC in estimating prognosis of GISTs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Chinese Medical Board Grant on Evidence-Based Medicine, New York, USA (No. 98-680), National Natural Science Foundation of China (No. 30901427)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Role of funding source: This work was supported by Chinese Medical Board Grant on Evidence-Based Medicine, New York, USA (No. 98-680), National Natural Science Foundation of China (No. 30901427).
Data Availability
The data referred to in the manuscript was available from the GEO dataset.
Abbreviations
- GIST
- gastrointestinal stromal tumor
- IPC
- immune-based prognostic classifier
- RFS
- recurrence free survival
- TAMs
- tumor-associated macrophages
- Tems
- effector memory T cells
- Tcms
- central memory T cells
- Tgd cells
- T Gamma/Delta cells
- TILs
- tumor infiltrating lymphocytes
- Tregs
- regulatory cells
- NIH
- National Institutes of Health
- UICC
- the Union for International Cancer Control
- AUC
- area under the curve
- PD-L1
- programmed death-ligand1
- NK
- natural killer
- LASSO
- least absolute shrinkage and selection operator method
- HR
- hazard ratio
- CI
- confidence interval
- ROC
- receiver operating characteristic
- DCA
- decision curve analysis
